secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001628280-24-007035
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q4/FY23 revenue growth 72%/54%; litigation resolved with $100M payment; FDA PDUFA March 31
--------------------------------------------------------------------------------

- FY23 U.S. net product revenue $78.3M (+40% YoY); total revenue $116.3M (+54% YoY).
- Q4 U.S. net product revenue $20.8M (+39% YoY); total revenue $32.3M (+72% YoY).
- Litigation with DSE resolved; $100M received Jan 2024, additional $25M pending EMA label determination.
- FDA PDUFA date March 31, 2024 for CV risk reduction label; Otsuka JNDA filing on track for 2024.
- Cash position boosted by $90.8M net equity offering and $100M litigation payment; 2024 OpEx guidance $225-245M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024007035/0001628280-24-007035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024007035/espr-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-007035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer